xom-20220617FALSE000003408800000340882022-06-172022-06-170000034088us-gaap:CommonStockMember2022-06-172022-06-170000034088xom:ZeroPointOneFourTwoPercentNotesDue2024Member2022-06-172022-06-170000034088xom:ZeroPointFiveTwoFourPercentNotesDue2028Member2022-06-172022-06-170000034088xom:ZeroPointFiveTwoFourPercentNotesDue2032Member2022-06-172022-06-170000034088xom:OnePointFourZeroEightPercentNotesDue2039Member2022-06-172022-06-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 17, 2022
Exxon Mobil Corporation
(Exact name of registrant as specified in its charter)
| | | | | | | | |
New Jersey | 1-2256 | 13-5409005 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
5959 Las Colinas Boulevard, Irving, Texas 75039-2298
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (972) 940-6000
| | |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| | Name of Each Exchange |
Title of Each Class | Trading Symbol | on Which Registered |
Common Stock, without par value | XOM | New York Stock Exchange |
0.142% Notes due 2024 | XOM24B | New York Stock Exchange |
0.524% Notes due 2028 | XOM28 | New York Stock Exchange |
0.835% Notes due 2032 | XOM32 | New York Stock Exchange |
1.408% Notes due 2039 | XOM39A | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
| |
Item 7.01 | Regulation FD Disclosure |
| |
On January 31, the Corporation announced in its News Release titled “ExxonMobil Streamlines Structure to Enhance Effectiveness, Grow Value, Reduce Costs” its intent to streamline its business structure to better support customers, enhance performance and grow value. Effective April 1, the Corporation formed ExxonMobil Product Solutions, combining world-scale Downstream and Chemical businesses, and centralized Technology & Engineering and Operations & Sustainability groups to further capture benefits of technology, scale, and integration value.
The Corporation will begin reporting under the new structure effective with the filing of the Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2022 that will be filed with the United States Securities and Exchange Commission (“SEC”). This Form 8-K provides a retrospective application of the new segments and reclassified historical results for the five (5) years prior to January 1, 2022 as shown in Exhibit 99.1. The adjustments to the new segmentation had no impact on the Corporation’s historical consolidated operating results, cash flows, or equity. Reclassified historical segment results are unaudited estimates. Exhibit 99.2 contains a presentation posted on our website explaining the restructuring and modeling guidance for our product solutions business. |
INDEX TO EXHIBITS
| | | | | |
Exhibit No. | Description |
| |
| New Segment Recast |
| |
| ExxonMobil Product Solutions Summary |
| |
104 | Cover Page Interactive Data File (formatted as Inline XBRL). |
| |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| EXXON MOBIL CORPORATION |
| | |
| | |
Date: June 17, 2022 | By: | /s/ LEN M. FOX |
| | Len M. Fox |
| | Vice President and Controller |
| | (Principal Accounting Officer) |
DocumentAttachment I - Earnings Recast
Reclassified historical segment results are unaudited estimates.
Due to rounding, numbers presented may not add up precisely to the totals indicated.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segmentation Basis (prior to 2Q22) | | | | | | | | | | | | | | | | | | | | | | | | |
Earnings/(Loss), $M | 1Q17 | 2Q17 | 3Q17 | 4Q17 | 2017 | 1Q18 | 2Q18 | 3Q18 | 4Q18 | 2018 | 1Q19 | 2Q19 | 3Q19 | 4Q19 | 2019 | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 2020 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 2021 | 1Q22 |
Upstream | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | (18) | (183) | (238) | 7,061 | 6,622 | 429 | 439 | 606 | 265 | 1,739 | 96 | 335 | 37 | 68 | 536 | (704) | (1,197) | (681) | (16,803) | (19,385) | 363 | 663 | 869 | 1,768 | 3,663 | 2,376 |
| Non-U.S. | 2,270 | 1,367 | 1,805 | 1,291 | 6,733 | 3,068 | 2,601 | 3,623 | 3,048 | 12,340 | 2,780 | 2,926 | 2,131 | 6,069 | 13,906 | 1,240 | (454) | 298 | (1,729) | (645) | 2,191 | 2,522 | 3,082 | 4,317 | 12,112 | 2,112 |
| Total | 2,252 | 1,184 | 1,567 | 8,352 | 13,355 | 3,497 | 3,040 | 4,229 | 3,313 | 14,079 | 2,876 | 3,261 | 2,168 | 6,137 | 14,442 | 536 | (1,651) | (383) | (18,532) | (20,030) | 2,554 | 3,185 | 3,951 | 6,085 | 15,775 | 4,488 |
Downstream | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | 292 | 347 | 391 | 918 | 1,948 | 319 | 695 | 961 | 987 | 2,962 | (161) | 310 | 673 | 895 | 1,717 | (101) | (101) | (136) | (514) | (852) | (113) | (149) | 663 | 913 | 1,314 | 685 |
| Non-U.S. | 824 | 1,038 | 1,141 | 646 | 3,649 | 621 | 29 | 681 | 1,717 | 3,048 | (95) | 141 | 557 | 3 | 606 | (510) | 1,077 | (95) | (697) | (225) | (277) | (78) | 592 | 554 | 791 | (353) |
| Total | 1,116 | 1,385 | 1,532 | 1,564 | 5,597 | 940 | 724 | 1,642 | 2,704 | 6,010 | (256) | 451 | 1,230 | 898 | 2,323 | (611) | 976 | (231) | (1,211) | (1,077) | (390) | (227) | 1,255 | 1,467 | 2,105 | 332 |
Chemical | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | 529 | 481 | 403 | 777 | 2,190 | 503 | 453 | 404 | 282 | 1,642 | 161 | (6) | 53 | (2) | 206 | 288 | 171 | 357 | 461 | 1,277 | 715 | 1,282 | 1,183 | 1,322 | 4,502 | 819 |
| Non-U.S. | 642 | 504 | 689 | 493 | 2,328 | 508 | 437 | 309 | 455 | 1,709 | 357 | 194 | 188 | (353) | 386 | (144) | 296 | 304 | 230 | 686 | 700 | 1,038 | 957 | 599 | 3,294 | 535 |
| Total | 1,171 | 985 | 1,092 | 1,270 | 4,518 | 1,011 | 890 | 713 | 737 | 3,351 | 518 | 188 | 241 | (355) | 592 | 144 | 467 | 661 | 691 | 1,963 | 1,415 | 2,320 | 2,140 | 1,921 | 7,796 | 1,354 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Corporate and Financing | (529) | (204) | (221) | (2,806) | (3,760) | (798) | (704) | (344) | (754) | (2,600) | (788) | (770) | (469) | (990) | (3,017) | (679) | (872) | (727) | (1,018) | (3,296) | (849) | (588) | (596) | (603) | (2,636) | (694) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net Income/(Loss) attributable to ExxonMobil (U.S. GAAP) | 4,010 | 3,350 | 3,970 | 8,380 | 19,710 | 4,650 | 3,950 | 6,240 | 6,000 | 20,840 | 2,350 | 3,130 | 3,170 | 5,690 | 14,340 | (610) | (1,080) | (680) | (20,070) | (22,440) | 2,730 | 4,690 | 6,750 | 8,870 | 23,040 | 5,480 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segmentation Basis (effective 2Q22) | | | | | | | | | | | | | | | | | | | | | | | | | |
Earnings/(Loss), $M | 1Q17 | 2Q17 | 3Q17 | 4Q17 | 2017 | 1Q18 | 2Q18 | 3Q18 | 4Q18 | 2018 | 1Q19 | 2Q19 | 3Q19 | 4Q19 | 2019 | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 2020 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 2021 | 1Q22 |
Upstream | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | (18) | (183) | (238) | 7,061 | 6,622 | 429 | 439 | 606 | 265 | 1,739 | 96 | 335 | 37 | 68 | 536 | (704) | (1,197) | (681) | (16,803) | (19,385) | 363 | 663 | 869 | 1,768 | 3,663 | 2,376 |
| Non-U.S. | 2,270 | 1,367 | 1,805 | 1,291 | 6,733 | 3,068 | 2,601 | 3,623 | 3,048 | 12,340 | 2,780 | 2,926 | 2,131 | 6,069 | 13,906 | 1,240 | (454) | 298 | (1,729) | (645) | 2,191 | 2,522 | 3,082 | 4,317 | 12,112 | 2,112 |
| Total | 2,252 | 1,184 | 1,567 | 8,352 | 13,355 | 3,497 | 3,040 | 4,229 | 3,313 | 14,079 | 2,876 | 3,261 | 2,168 | 6,137 | 14,442 | 536 | (1,651) | (383) | (18,532) | (20,030) | 2,554 | 3,185 | 3,951 | 6,085 | 15,775 | 4,488 |
Energy Products | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | 255 | 263 | 319 | 856 | 1,693 | 279 | 631 | 953 | 1,059 | 2,922 | (195) | 203 | 589 | 828 | 1,425 | (183) | (212) | (300) | (648) | (1,342) | (232) | (278) | 479 | 699 | 668 | 489 |
| Non-U.S. | 594 | 655 | 804 | 425 | 2,477 | 400 | (172) | 559 | 1,561 | 2,348 | (175) | 21 | 335 | (164) | 17 | (645) | 895 | (399) | (1,081) | (1,230) | (689) | (578) | 50 | 203 | (1,014) | (684) |
| Total | 849 | 918 | 1,122 | 1,280 | 4,170 | 679 | 459 | 1,512 | 2,620 | 5,270 | (369) | 223 | 924 | 664 | 1,442 | (828) | 683 | (699) | (1,728) | (2,572) | (921) | (856) | 529 | 901 | (347) | (196) |
Chemical Products | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | 426 | 389 | 342 | 598 | 1,754 | 441 | 382 | 313 | 203 | 1,339 | 103 | (23) | 2 | 14 | 97 | 220 | 174 | 364 | 439 | 1,196 | 654 | 1,149 | 1,121 | 774 | 3,697 | 770 |
| Non-U.S. | 571 | 482 | 663 | 509 | 2,225 | 492 | 483 | 293 | 388 | 1,655 | 332 | 289 | 298 | (240) | 679 | (4) | 278 | 360 | 427 | 1,061 | 737 | 1,051 | 907 | 597 | 3,292 | 636 |
| Total | 997 | 870 | 1,005 | 1,107 | 3,979 | 933 | 865 | 606 | 591 | 2,994 | 435 | 266 | 301 | (226) | 776 | 215 | 451 | 724 | 866 | 2,257 | 1,391 | 2,200 | 2,027 | 1,371 | 6,989 | 1,405 |
Specialty Products | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | 140 | 176 | 133 | 241 | 691 | 101 | 135 | 99 | 8 | 343 | 92 | 124 | 134 | 51 | 401 | 151 | 108 | 156 | 156 | 571 | 180 | 262 | 247 | 763 | 1,452 | 246 |
| Non-U.S. | 301 | 406 | 364 | 205 | 1,276 | 238 | 155 | 138 | 223 | 754 | 105 | 26 | 112 | 54 | 296 | (5) | 200 | 248 | 187 | 630 | 375 | 487 | 592 | 353 | 1,807 | 230 |
| Total | 441 | 582 | 497 | 446 | 1,966 | 339 | 290 | 237 | 231 | 1,097 | 196 | 150 | 246 | 105 | 697 | 146 | 309 | 405 | 342 | 1,201 | 555 | 750 | 839 | 1,116 | 3,259 | 476 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Corporate and Financing | (529) | (204) | (221) | (2,806) | (3,760) | (798) | (704) | (344) | (754) | (2,600) | (788) | (770) | (469) | (990) | (3,017) | (679) | (872) | (727) | (1,018) | (3,296) | (849) | (588) | (596) | (603) | (2,636) | (694) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net Income/(Loss) attributable to ExxonMobil (U.S. GAAP) | 4,010 | 3,350 | 3,970 | 8,380 | 19,710 | 4,650 | 3,950 | 6,240 | 6,000 | 20,840 | 2,350 | 3,130 | 3,170 | 5,690 | 14,340 | (610) | (1,080) | (680) | (20,070) | (22,440) | 2,730 | 4,690 | 6,750 | 8,870 | 23,040 | 5,480 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Attachment II - Identified Items Recast
Reclassified historical segment results are unaudited estimates.
Due to rounding, numbers presented may not add up precisely to the totals indicated.
As per previously reported data. Identified items as per frequently used terms from 2018 onwards. 2017 data shows reported Asset Impairments and U.S. Tax reform impacts.
Earnings/(loss) excluding identified items are earnings/(loss) excluding individually significant non-operational events with an absolute corporate total earnings impact of at least $250 million in a given quarter. The earnings/(loss) impact of an identified item for an individual segment may be less than $250 million when the item impacts several periods or several segments. Earnings/(loss) excluding identified items does include non-operational earnings events or impacts that are below the $250 million threshold utilized for identified items. When the effect of these events are material in aggregate, they are indicated in analysis of period results as part of quarterly earnings press release and teleconference materials. Management uses these figures to improve comparability of the underlying business across multiple periods by isolating and removing significant non-operational events from business results. The Corporation believes this view provides investors increased transparency into business results and trends, and provides investors with a view of the business as seen through the eyes of management. Earnings excluding identified items is not meant to be viewed in isolation or as a substitute for net income/(loss) attributable to ExxonMobil as prepared in accordance with U.S. GAAP.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segmentation Basis (prior to 2Q22) | | | | | | | | | | | | | | | | | | | | | | | | | | |
Identified Items Earnings/(Loss), $M | 1Q17 | 2Q17 | 3Q17 | 4Q17 | 2017 | 1Q18 | 2Q18 | 3Q18 | 4Q18 | 2018 | 1Q19 | 2Q19 | 3Q19 | 4Q19 | 2019 | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 2020 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 2021 | 1Q22 |
Upstream | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | Impairments | — | — | (40) | (481) | (521) | — | — | — | — | — | — | — | — | — | — | (315) | — | — | (16,777) | (17,092) | — | — | — | (263) | (263) | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (45) | 45 | — | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 7,602 | 7,602 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (274) | (274) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | (40) | 7,121 | 7,081 | — | — | — | (274) | (274) | — | — | — | — | — | (360) | 45 | — | (16,777) | (17,092) | — | — | — | (263) | (263) | — |
| Non-U.S. | Impairments | — | (118) | (58) | (807) | (983) | — | — | — | — | — | — | — | — | — | — | (41) | — | — | (2,203) | (2,244) | — | — | — | (489) | (489) | (2,877) |
| | Gain/(loss) on sale of assets | — | — | — | — | — | 366 | — | — | — | 366 | — | — | — | 3,679 | 3,679 | — | — | — | — | — | — | — | — | 459 | 459 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (218) | 168 | (11) | — | (61) | — | — | — | — | — | — |
| | Tax-related items | — | — | — | (480) | (480) | — | — | 271 | — | 271 | — | 487 | — | 268 | 755 | — | — | — | (297) | (297) | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (96) | (96) | — | — | — | — | — | — | — | — | — | — | — | — | — | (250) | (250) | (378) |
| | Total | — | (118) | (58) | (1,287) | (1,463) | 366 | — | 271 | (96) | 541 | — | 487 | — | 3,947 | 4,434 | (259) | 168 | (11) | (2,500) | (2,602) | — | — | — | (280) | (280) | (3,255) |
| Total | Impairments | — | (118) | (98) | (1,288) | (1,504) | — | — | — | — | — | — | — | — | — | — | (356) | — | — | (18,980) | (19,336) | — | — | — | (752) | (752) | (2,877) |
| | Gain/(loss) on sale of assets | — | — | — | — | — | 366 | — | — | — | 366 | — | — | — | 3,679 | 3,679 | — | — | — | — | — | — | — | — | 459 | 459 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (263) | 213 | (11) | — | (61) | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 7,122 | 7,122 | — | — | 271 | — | 271 | — | 487 | — | 268 | 755 | — | — | — | (297) | (297) | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (370) | (370) | — | — | — | — | — | — | — | — | — | — | — | — | — | (250) | (250) | (378) |
| | Total | — | (118) | (98) | 5,834 | 5,618 | 366 | — | 271 | (370) | 267 | — | 487 | — | 3,947 | 4,434 | (619) | 213 | (11) | (19,277) | (19,694) | — | — | — | (543) | (543) | (3,255) |
Downstream | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | Impairments | — | — | — | (6) | (6) | — | — | — | — | — | — | — | — | — | — | (4) | — | — | — | (4) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (407) | 404 | 3 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 618 | 618 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | — | 612 | 612 | — | — | — | — | — | — | — | — | — | — | (411) | 404 | 3 | — | (4) | — | — | — | 4 | 4 | — |
| Non-U.S. | Impairments | — | — | (11) | — | (11) | — | — | — | — | — | — | — | — | — | — | (335) | — | — | (258) | (593) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | 888 | 888 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (1,196) | 1,190 | 6 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | — | — | — | — | — | 57 | 57 | — | (9) | — | — | (9) | — | — | — | (262) | (262) | — | — | — | — | — | — |
| | Total | — | — | (11) | — | (11) | — | — | — | 945 | 945 | — | (9) | — | — | (9) | (1,531) | 1,190 | 6 | (520) | (855) | — | — | — | — | — | — |
| Total | Impairments | — | — | (11) | (6) | (17) | — | — | — | — | — | — | — | — | — | — | (339) | — | — | (258) | (597) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | 888 | 888 | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (1,603) | 1,594 | 9 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 618 | 618 | — | — | — | 57 | 57 | — | (9) | — | — | (9) | — | — | — | (262) | (262) | — | — | — | — | — | — |
| | Total | — | — | (11) | 612 | 601 | — | — | — | 945 | 945 | — | (9) | — | — | (9) | (1,942) | 1,594 | 9 | (520) | (859) | — | — | — | 4 | 4 | — |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segmentation Basis (prior to 2Q22)- Continued | | | | | | | | | | | | | | | | | | | | | | | | | | |
Identified Items Earnings/(Loss), $M | 1Q17 | 2Q17 | 3Q17 | 4Q17 | 2017 | 1Q18 | 2Q18 | 3Q18 | 4Q18 | 2018 | 1Q19 | 2Q19 | 3Q19 | 4Q19 | 2019 | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 2020 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 2021 | 1Q22 |
Chemical | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | Impairments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (90) | — | — | — | (90) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 494 | 494 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (29) | 29 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 335 | 335 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | — | 335 | 335 | — | — | — | — | — | — | — | — | — | — | (90) | (29) | 29 | — | (90) | — | — | — | 494 | 494 | — |
| Non-U.S. | Impairments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (2) | — | — | — | (2) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 136 | 136 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (230) | 144 | 86 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | — | — | — | — | — | 212 | 212 | — | 2 | — | — | 2 | — | — | — | (22) | (22) | — | — | — | — | — | — |
| | Total | — | — | — | — | — | — | — | — | 212 | 212 | — | 2 | — | — | 2 | (232) | 144 | 86 | (22) | (24) | — | — | — | 136 | 136 | — |
| Total | Impairments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (92) | — | — | — | (92) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 630 | 630 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (230) | 115 | 115 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 335 | 335 | — | — | — | 212 | 212 | — | 2 | — | — | 2 | — | — | — | (22) | (22) | — | — | — | — | — | — |
| | Total | — | — | — | 335 | 335 | — | — | — | 212 | 212 | — | 2 | — | — | 2 | (322) | 115 | 115 | (22) | (114) | — | — | — | 630 | 630 | — |
Corporate and Financing | Impairments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (35) | (35) | — | — | — | — | — | (98) |
Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | (6) | (6) | — | — | — | (24) | (24) | — | — | — | — | — | — | — | — | (12) | (12) | — |
| | Severance | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (326) | (326) | (31) | (12) | (5) | (4) | (52) | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | (2,133) | (2,133) | — | — | 348 | — | 348 | — | 25 | 307 | — | 332 | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | — | (2,133) | (2,133) | — | — | 348 | (6) | 342 | — | 25 | 307 | (24) | 308 | — | — | — | (361) | (361) | (31) | (12) | (5) | (16) | (64) | (98) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Identified items impact attributable to ExxonMobil | Impairments | — | (118) | (109) | (1,294) | (1,521) | — | — | — | — | — | — | — | — | — | — | (787) | — | — | (19,273) | (20,060) | — | — | — | (752) | (752) | (2,975) |
Gain/(loss) on sale of assets | — | — | — | — | — | 366 | — | — | 882 | 1,248 | — | — | — | 3,655 | 3,655 | — | — | — | — | — | — | — | — | 1,081 | 1,081 | — |
| | Severance | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (326) | (326) | (31) | (12) | (5) | (4) | (52) | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (2,096) | 1,922 | 113 | — | (61) | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 5,942 | 5,942 | — | — | 619 | 269 | 888 | — | 505 | 307 | 268 | 1,080 | — | — | — | (581) | (581) | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (370) | (370) | — | — | — | — | — | — | — | — | — | — | — | — | — | (250) | (250) | (378) |
| | Total | — | (118) | (109) | 4,648 | 4,421 | 366 | — | 619 | 781 | 1,766 | — | 505 | 307 | 3,923 | 4,735 | (2,883) | 1,922 | 113 | (20,180) | (21,028) | (31) | (12) | (5) | 75 | 27 | (3,353) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segmentation Basis (effective 2Q22) | | | | | | | | | | | | | | | | | | | | | | | | | | |
Identified Items Earnings/(Loss), $M | 1Q17 | 2Q17 | 3Q17 | 4Q17 | 2017 | 1Q18 | 2Q18 | 3Q18 | 4Q18 | 2018 | 1Q19 | 2Q19 | 3Q19 | 4Q19 | 2019 | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 2020 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 2021 | 1Q22 |
Upstream | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | Impairments | — | — | (40) | (481) | (521) | — | — | — | — | — | — | — | — | — | — | (315) | — | — | (16,777) | (17,092) | — | — | — | (263) | (263) | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (45) | 45 | — | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 7,602 | 7,602 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (274) | (274) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | (40) | 7,121 | 7,081 | — | — | — | (274) | (274) | — | — | — | — | — | (360) | 45 | — | (16,777) | (17,092) | — | — | — | (263) | (263) | — |
| Non-U.S. | Impairments | — | (118) | (58) | (807) | (983) | — | — | — | — | — | — | — | — | — | — | (41) | — | — | (2,203) | (2,244) | — | — | — | (489) | (489) | (2,877) |
| | Gain/(loss) on sale of assets | — | — | — | — | — | 366 | — | — | — | 366 | — | — | — | 3,679 | 3,679 | — | — | — | — | — | — | — | — | 459 | 459 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (218) | 168 | (11) | — | (61) | — | — | — | — | — | — |
| | Tax-related items | — | — | — | (480) | (480) | — | — | 271 | — | 271 | — | 487 | — | 268 | 755 | — | — | — | (297) | (297) | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (96) | (96) | — | — | — | — | — | — | — | — | — | — | — | — | — | (250) | (250) | (378) |
| | Total | — | (118) | (58) | (1,287) | (1,463) | 366 | — | 271 | (96) | 541 | — | 487 | — | 3,947 | 4,434 | (259) | 168 | (11) | (2,500) | (2,602) | — | — | — | (280) | (280) | (3,255) |
| Total | Impairments | — | (118) | (98) | (1,288) | (1,504) | — | — | — | — | — | — | — | — | — | — | (356) | — | — | (18,980) | (19,336) | — | — | — | (752) | (752) | (2,877) |
| | Gain/(loss) on sale of assets | — | — | — | — | — | 366 | — | — | — | 366 | — | — | — | 3,679 | 3,679 | — | — | — | — | — | — | — | — | 459 | 459 | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (263) | 213 | (11) | — | (61) | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 7,122 | 7,122 | — | — | 271 | — | 271 | — | 487 | — | 268 | 755 | — | — | — | (297) | (297) | — | — | — | — | — | — |
| | Other | — | — | — | — | — | — | — | — | (370) | (370) | — | — | — | — | — | — | — | — | — | — | — | — | — | (250) | (250) | (378) |
| | Total | — | (118) | (98) | 5,834 | 5,618 | 366 | — | 271 | (370) | 267 | — | 487 | — | 3,947 | 4,434 | (619) | 213 | (11) | (19,277) | (19,694) | — | — | — | (543) | (543) | (3,255) |
Energy Products | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | Impairments | — | — | — | (6) | (6) | — | — | — | — | — | — | — | — | — | — | (4) | — | — | — | (4) | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (407) | 399 | 8 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 581 | 581 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | — | 575 | 575 | — | — | — | — | — | — | — | — | — | — | (411) | 399 | 8 | — | (4) | — | — | — | — | — | — |
| Non-U.S. | Impairments | — | — | (11) | — | (11) | — | — | — | — | — | — | — | — | — | — | (116) | — | — | (258) | (374) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | 847 | 847 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (1,302) | 1,290 | 12 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | — | — | — | — | — | 49 | 49 | — | (9) | — | — | (9) | — | — | — | (262) | (262) | — | — | — | — | — | — |
| | Total | — | — | (11) | — | (11) | — | — | — | 896 | 896 | — | (9) | — | — | (9) | (1,418) | 1,290 | 12 | (520) | (636) | — | — | — | — | — | — |
| Total | Impairments | — | — | (11) | (6) | (17) | — | — | — | — | — | — | — | — | — | — | (120) | — | — | (258) | (378) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | 847 | 847 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (1,709) | 1,689 | 20 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 581 | 581 | — | — | — | 49 | 49 | — | (9) | — | — | (9) | — | — | — | (262) | (262) | — | — | — | — | — | — |
| | Total | — | — | (11) | 575 | 564 | — | — | — | 896 | 896 | — | (9) | — | — | (9) | (1,829) | 1,689 | 20 | (520) | (640) | — | — | — | — | — | — |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Segmentation Basis (effective 2Q22)- Continued | | | | | | | | | | | | | | | | | | | | | | | | | | |
Identified Items Earnings/(Loss), $M | 1Q17 | 2Q17 | 3Q17 | 4Q17 | 2017 | 1Q18 | 2Q18 | 3Q18 | 4Q18 | 2018 | 1Q19 | 2Q19 | 3Q19 | 4Q19 | 2019 | 1Q20 | 2Q20 | 3Q20 | 4Q20 | 2020 | 1Q21 | 2Q21 | 3Q21 | 4Q21 | 2021 | 1Q22 |
Chemical Products | | | | | | | | | | | | | | | | | | | | | | | | | | |
| United States | Impairments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (90) | — | — | — | (90) | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (19) | 19 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | 215 | 215 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Total | — | — | — | 215 | 215 | — | — | — | — | — | — | — | — | — | — | (90) | (19) | 19 | — | (90) | — | — | — | — | — | — |
| Non-U.S. | Impairments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (2) | — | — | — | (2) | — | — | — | — | — | — |
| | Gain/(loss) on sale of assets | — | — | — | — | — | — | — | — | 1 | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| | Inventory valuation - lower of cost or market | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (124) | 60 | 64 | — | — | — | — | — | — | — | — |
| | Tax-related items | — | — | — | — | — | — | — | — | 155 | 155 | — | 2 | — | — | 2 | — | — | — | (13) | (13) | — | — | — | — | — | — |
| | Total | — | — | — | — | — | — | — | — | 156 | 156 | — | 2 | — | — | 2 | (126) | 60 | 64 | (13) | (15) | — | — | — | — | |